News & Events about 2seventy Bio Inc.
2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, will announce its first quarter 2023 financial results on Wednesday, May 3, 2023. 2seventy bio will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide a business update...
Continued progress in 2022 with corporate strategy update, end-to-end platform innovation, pipeline expansion, and acceleration of lead candidate developmentPartnering momentum continues with a $3 million milestone payment from 2seventy bioStrengthened leadership with key hires in Corporate ...
2seventy bio, Inc. (Nasdaq: TSVT) today announced the appointment of Wei Lin, M.D. to the companys Board of Directors, effective immediately. We are thrilled to welcome Dr. Wei Lin to 2seventys Board during an exciting time in our Companys growth, said Nick Leschly, chief kairos officer. Weis...
2seventy bio, Inc. (Nasdaq: TSVT) announced today that members of the management team will present at the 43rd Annual TD Cowen Health Care Conference at the Boston Marriott Copley Place in Boston, MA on March 7, 2023 at 10:30am ET. A live webcast will be available via the Investors and...
2seventy bio, Inc. (2seventy bio) (Nasdaq: TSVT), a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer, announced today the pricing of a follow on underwritten public offering of 10,869,566 shares of its common stock at...